entertainment -WSS

entertainment

author：focus 2025-09-28 21:07:00 - browse：8771

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： JPM: CVS says Medicare Advantage patients are impacting profits

WSS

After Sarepta trial failure, Duchenne families brace for more debate

Gene therapy’s promise and the high cost of hope

The health care issue Democrats can’t solve: hospital reform

Videos point to link between seizures and unexplained toddler deaths

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Prime Medicine says its gene editing passes test in monkeys

knowledge

entertainment

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Heart attack and stroke risk calculators need revising

Inari Medical to buy amputation prevention company LimFlow

How to save PrEP access — and even expand it

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Dobbs anniversary: the lost opportunity of abortion as health care

U.K. sequencing study surfaces new findings about tumor DNA

leisure time

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Antibiotic resistance and the global rise in human conflict

The health care issue Democrats can’t solve: hospital reform

Videos point to link between seizures and unexplained toddler deaths

How neuroscience research could help beat back brain cancer

Why psychiatrists like me stop taking insurance

focus

knowledge

hotspot

focus